We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Palatin Technologies Inc New | AMEX:PTN | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.07 | -3.32% | 2.04 | 2.21 | 1.9717 | 2.12 | 375,390 | 00:26:40 |
CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company's President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference on Thursday, August 11th, 2016 at 1:00 p.m. Eastern time. The conference is being held at the InterContinental Boston, Boston, MA August 10-11, 2016.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/palatin-technologies-to-present-at-the-36th-annual-canaccord-genuity-growth-conference-300310390.html
SOURCE Palatin Technologies, Inc.
Copyright 2016 PR Newswire
1 Year Palatin Technologies Chart |
1 Month Palatin Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions